AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
185 hedge funds and large institutions have $1.01B invested in AMAG Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 76 increasing their positions, 42 reducing their positions, and 30 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 42
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
47% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 30
8% more funds holding
Funds holding: 172 → 185 (+13)
1.01% less ownership
Funds ownership: 127.19% → 126.18% (-1%)
23% less capital invested
Capital invested by funds: $1.32B → $1.01B (-$306M)
99% less call options, than puts
Call options by funds: $1.82M | Put options by funds: $175M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$36.3M |
| 2 |
SIM
Stelliam Investment Management
New York
|
+$18.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$14.2M |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$9.04M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$31.8M |
| 2 |
Millennium Management
New York
|
-$29.3M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$26.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.7M |
| 5 |
PC
PointState Capital
New York
|
-$12.1M |
AMAG Hedge Fund Activity: Q1 2016 in Review
185 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q1 2016, worth a combined $1.01B — down 23% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new AMAG positions and 30 closed out — a net gain of 14 holders — while 76 added to existing stakes and 42 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $36.3M. The largest seller was Westfield Capital Management, cutting an estimated $31.8M.
- 185 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q1 2016, up from 172 in Q4 2015.
- Funds reported $1.01B of AMAG Pharmaceuticals stock for Q1 2016, down 23% quarter-over-quarter.
- 44 funds opened new AMAG Pharmaceuticals positions in Q1 2016 and 30 closed out, a net change of +14 holders.
- The largest AMAG Pharmaceuticals buyer in Q1 2016 was BlackRock Fund Advisors, an estimated $36.3M added.
- The largest AMAG Pharmaceuticals seller in Q1 2016 was Westfield Capital Management, an estimated $31.8M sold.
Based on aggregated 13F filings for Q1 2016.